CMXHF - CSL Limited

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
At close: 11:49AM EST
Stock chart is not supported by your current browser
Previous Close107.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume237
Market Cap49.63B
PE Ratio (TTM)36.51
EPS (TTM)2.93
Earnings DateN/A
Forward Dividend & Yield1.43 (1.34%)
Ex-Dividend Date2017-09-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • Best Growth Stock Picks
    Simply Wall St.10 days ago

    Best Growth Stock Picks

    Analysts are bullish on these following companies: Class, Imdex, CSL. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. Below I’veRead More...

  • The Wall Street Journal3 months ago

    [$$] CSL Behring to Buy Biotech Startup Calimmune for $416 Million

    The global biotherapeutics company will to pay $91 million cash and $325 million in milestones to acquire venture-backed Calimmune Inc. and its potential gene therapy for two rare blood disorders.

  • Momenta (MNTA) to Receive $50M Under CSL Collaboration
    Zacks10 months ago

    Momenta (MNTA) to Receive $50M Under CSL Collaboration

    Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

  • Bloomberg11 months ago

    American Blood Gives a Boost to Asia’s Most Valuable Drugmaker

    Twice a week, thousands of people across the U.S. roll up their sleeves and give almost a liter of their blood plasma -- which will eventually be made into dozens of pharmaceutical products.